Table 1.
Variable | n | Female | Male | Percentage of the totals (%) |
---|---|---|---|---|
Clinical outcome as of June 2013 | ||||
Alive and active in care | 792 | 442 | 350 | (65) |
Dead | 27 | 13 | 14 | (2) |
LTFU | 400 | 236 | 164 | (32) |
Transferred | 9 | 6 | 3 | (1) |
Site of participant | ||||
Entebbe | 103 | 58 | 45 | (9) |
Gulu | 97 | 65 | 32 | (8) |
Jinja | 99 | 53 | 46 | (8) |
Masaka | 170 | 112 | 58 | (14) |
Mbale | 163 | 92 | 71 | (13) |
Mbarara | 131 | 71 | 60 | (11) |
Masindi | 62 | 34 | 28 | (5) |
Rukungiri | 131 | 68 | 63 | (11) |
Soroti | 128 | 68 | 60 | (11) |
Tororo | 144 | 76 | 68 | (11) |
Age (years) | ||||
10–14 | 750 | 400 | 350 | (61) |
15–19 | 478 | 297 | 181 | (39) |
Highest level of education | ||||
None | 223 | 119 | 104 | (18) |
Primary | 894 | 516 | 378 | (73) |
Secondary and above | 111 | 62 | 49 | (9) |
Venue of ARV refill | ||||
CDDP | 476 | 278 | 198 | (39) |
Health facility | 752 | 419 | 333 | (61) |
Marital status | ||||
Single | 1170 | 660 | 510 | (78) |
Married | 58 | 37 | 21 | (3) |
CD4 at ART initiation | ||||
<250 cells/mm3 | 851 | 486 | 365 | (69) |
≥250 cells/mm3 | 377 | 211 | 166 | (31) |
Year of ART initiation | ||||
2006–2008 | 453 | 243 | 210 | (37) |
2009–2011 | 775 | 454 | 321 | (63) |
WHO stage (n=984) | ||||
Stage 1&2 | 725 | 417 | 308 | (74) |
Stage 3 | 218 | 133 | 85 | (22) |
Stage 4 | 41 | 20 | 21 | (4) |
LTFU, lost to follow-up; CDDP, community drug distribution point.